A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Collaborator: Otsuka America Pharmaceutical
• Treatments: Antidepressive Agents; Aripiprazole

Criteria

Inclusion Criteria:

• Men and women, 18 years or older

• Experiencing Major Depressive Disorder with a duration of minimally 8 weeks.

• Treatment history of an inadequate response to at least one and no more than four antidepressants